





TAPINAROF



First-in-class Aryl hydrocarbon Receptor (AhR)- Agonist





Approved in the United States in May 2022 for the treatment of Psoriasis and Atopic Dermatitis.

Mechanism of Action:

Tapinarof acts as an aryl hydrocarbon receptor (AhR) agonist. By selectively activating AhR, a ligand-activated transcription factor expressed in skin cells, tapinarof modulates gene expression involved in skin barrier function, inflammation, and oxidative stress. This mechanism contributes to its anti-inflammatory and immune-regulating properties, making it effective in treating chronic skin disorders such as plaque psoriasis and atopic dermatitis. Unlike traditional immunosuppressants or corticosteroids, tapinarof offers a non-steroidal approach, potentially reducing long-term safety concerns while delivering durable therapeutic benefits.





Psoriasis Market Overview & Forecast:


In 2024, the psoriasis treatment market was valued at USD 20.3 billion across the top 7 markets, and is expected to grow to USD 38.4 billion by 2035, at a CAGR of ~5.96% from 2025 to 2035

Atopic Dermatitis Market Overview & Forecast:

the global AD market across the 7 major markets (7MM) was valued at approximately USD 18.08 billion in 2024, and is expected to grow to USD 40.23 billion by 2035, with a CAGR of 7.55% between 2025 and 2035

Tapinarof Market Projection:

GlobalData forecasts that Tapinarof could generate approximately USD 766 million in sales by 2030 in atopic dermatitis alone, assuming regulatory approvals are secured globally



What we can offer

- Tapinarof for test and Development activities.
- Process Impurities.
- Tapinarof API (Bulk), OR
- **Novel improved process for Tapinarof manufacturing:**
Detailed tech-pack for Tapinarof manufacturing, including Analytical Method, and working reference standard of intermediates and impurities.
- **Exclusive right for a novel improved process:**
An Indian provisional patent has been filed for the Improved process of Tapinarof Manufacturing.



K-1006, Dynasty, Kaspate Wasti, Wakad,
Pune-411057, INDIA



info@synvisionchem.com
www.synvisionchem.com

